pharma · Hepatocellular Carcinoma · Obesity
Hospital Authority
Hospital Authority, Hong Kong
Hospital Authority clinical programs — 322 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Hospital Authority Building, 147B Argyle Street, Kowloon, Hong Kong, 852, HK, CN
- Founded
- 1991
- Employees
- 12,669
- Programs
- 322
- Drugs
- 301
- Patents
- 0
Hospital Authority projects
322 ClinicalTrials.gov programs sponsored by Hospital Authority.
Hospital Authority has 322 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Warfarin Sodium
Hospital Authority, Hong Kong
Indications for Warfarin Therapy
1 trial -
cilostazol
Hospital Authority, Hong Kong
Coronary Artery Stenosis
1 trial -
dydrogesterone
Hospital Authority, Hong Kong
Preterm Delivery
1 trial -
filgrastim
Hospital Authority, Hong Kong
Brain and Central Nervous System Tumors
2 trials -
individual lactation counseling and educational material
Hospital Authority, Hong Kong
Breastfeeding
1 trial -
induced moderate hypothermia
Hospital Authority, Hong Kong
Traumatic Brain Injury
1 trial -
iron isomaltoside(Monofer®)
Hospital Authority, Hong Kong
Anemia, Iron-Deficiency
1 trial -
laser acupuncture
Hospital Authority, Hong Kong
Postpartum Weight Retention
1 trial -
magnetic stimulation
Hospital Authority, Hong Kong
Neuropathic Pain
1 trial -
one percent ultrasound power in CMICS
Hospital Authority, Hong Kong
Cataract
1 trial -
platelet-rich plasma combined with hyaluronic acid
Hospital Authority, Hong Kong
Traumatic Olfactory Nerve Injury With Anosmia (Diagnosis)
1 trial -
robot-assisted surgery
Hospital Authority, Hong Kong
Rectal Cancer
1 trial -
total knee arthroplasty
Hospital Authority, Hong Kong
Osteoarthritis, Knee
1 trial -
12.5mg sunitinib with Cisplatin and Gemcitabine
Hospital Authority, Hong Kong
Nasopharyngeal Carcinoma
1 trial -
5% MInoxidil milky lotion
Hospital Authority, Hong Kong
Objective (Goal)
1 trial -
5-Fluorouracil
Hospital Authority, Hong Kong
Cancer (Advanced Stage)
1 trial -
AS01 adjuvant (0.5 mL intramuscular)
Hospital Authority, Hong Kong
Immune System Responses and Trained Immunity After AS01 Administration
1 trial -
ASLAN001
Hospital Authority, Hong Kong
Advanced/ Metastatic Hepatocellular Carcinoma
1 trial -
AZD9291
Hospital Authority, Hong Kong
Carcinoma, Non-Small-Cell Lung
1 trial -
Allogenic expanded Natural Killer Cells (AlloNK1)
Hospital Authority, Hong Kong
Nasopharyngeal Carcinoma (NPC)
1 trial -
Apatinib
Hospital Authority, Hong Kong
Soft Tissue Sarcoma, Adult, Stage II
1 trial -
Arm1
Hospital Authority, Hong Kong
Oral Squamous Cell Carcinoma
1 trial -
Art-BTC
Hospital Authority, Hong Kong
Biliary Cancer Metastatic
1 trial -
Atorvastatin
Hospital Authority, Hong Kong
Vitiligo
1 trial -
Avatrombopag
Hospital Authority, Hong Kong
Chemotherapy-induced Thrombocytopenia
1 trial -
BMMNCs
Hospital Authority, Hong Kong
Retinitis Pigmentosa
1 trial -
BPF-CCRT (run-in)
Hospital Authority, Hong Kong
Stage III Esophageal Squamous Cell Carcinoma
1 trial -
Bovine colostrum
Hospital Authority, Hong Kong
Severe Alcoholic Hepatitis in 'Extremis'- Defined by mDF>54
1 trial -
CART infusion
Hospital Authority, Hong Kong
B-cell Lymphoma Refractory
1 trial -
Cholecalciferol
Hospital Authority, Hong Kong
Hematologic Neoplasms
1 trial -
Coriolus Versicolor
Hospital Authority, Hong Kong
Carcinoma
1 trial -
Cutting balloon followed by paclitaxel coated balloon
Hospital Authority, Hong Kong
Dialysis Access Malfunction
1 trial -
Cytarabine
Hospital Authority, Hong Kong
AML
1 trial -
DAOIB
Hospital Authority, Hong Kong
Long COVID
1 trial -
DRUID AI Program
Hospital Authority, Hong Kong
Solid Organ Malignancies
1 trial -
Darovasertib
Hospital Authority, Hong Kong
Ocular Melanoma
1 trial -
Daunorubicin
Hospital Authority, Hong Kong
Down Syndrome
1 trial -
Dental stent
Hospital Authority, Hong Kong
Nasopharyngeal Carcinoma
1 trial -
Docetaxel
Hospital Authority, Hong Kong
Non Small Cell Lung Cancer
1 trial -
Dostarlimab
Hospital Authority, Hong Kong
Female
1 trial -
Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD)
Hospital Authority, Hong Kong
Benign Prostatic Hyperplasia
1 trial -
Doxycycline
Hospital Authority, Hong Kong
Tuberculosis, Meningeal
1 trial -
Drug: Pembrolizumab
Hospital Authority, Hong Kong
Clear-cell Metastatic Renal Cell Carcinoma
1 trial -
Dupilumab
Hospital Authority, Hong Kong
Nephrotic Syndrome in Children
1 trial -
Expanded , Activated NK cells
Hospital Authority, Hong Kong
Ewing Sarcoma
1 trial -
FEMH-95011
Hospital Authority, Hong Kong
Stomach Neoplasms
1 trial -
Faropenem
Hospital Authority, Hong Kong
Pulmonary Tuberculosis
1 trial -
Hyperpolarized 13C-Pyruvate injection
Hospital Authority, Hong Kong
Gynecologic Cancer
1 trial
Frequently asked questions
How many clinical projects does Hospital Authority have?
322 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.